Is Edwards Lifesciences (EW) Share Price Getting Ahead Of Its Fundamentals After Recent Gains

• Wondering if Edwards Lifesciences at around US$87.54 is still a fair deal or starting to look stretched? This article focuses squarely on what the current price suggests about value.
• The stock has recently delivered returns of 6.5% over the past week, 4.0% over the last 30 days, 2.6% year to date, and 14.9% over the past year, which can change how investors think about both opportunity and risk.
• Recent coverage has largely centered on Edwards Lifesciences as a key player in medical equipment and heart valve technologies, with investors weighing its position in this sector against current pricing. This backdrop helps explain why the stock's recent moves are drawing attention from both long term holders and new investors looking for clear valuation signals.
• On Simply Wall St's valuation checklist the stock scores 1 out of 6 checks for being undervalued, as shown in the valuation score. Next up is a closer look at standard valuation methods and, importantly, a more complete way to think about value that ties them all together.

Edwards Lifesciences scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Edwards Lifesciences Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and then discounting them back to today’s value using a required rate of return.

For Edwards Lifesciences, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve-month free cash flow is about $1.05b. Analyst estimates and Simply Wall St projections suggest free cash flow reaching $1.93b in 2028, with further annual projections out to 2035, all converted into today’s dollars.

When all those projected cash flows are added and discounted, the intrinsic value from this DCF comes out at about $89.27 per share. Compared with the current share price of about $87.54, the model implies the stock is trading at roughly a 1.9% discount, which is a very small gap.

Overall, based on this DCF view, Edwards Lifesciences appears close to fairly priced with only a mild lean toward value.

Result: ABOUT RIGHT

Edwards Lifesciences is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Edwards Lifesciences.

Approach 2: Edwards Lifesciences Price vs Earnings

For profitable companies, the P/E ratio is a useful cross check, because it links what you pay per share to the earnings that the business is already generating. Investors usually accept a higher P/E when they expect stronger growth and lower perceived risk, and a lower P/E when growth is more modest or risks feel higher.

Edwards Lifesciences currently trades on a P/E of about 46.9x. That sits well above the Medical Equipment industry average of about 24.4x and also above the broader peer average of about 25.0x, which suggests the stock is priced at a premium to many sector peers.

Simply Wall St’s Fair Ratio concept takes this a step further. It estimates what a “normal” P/E might be for Edwards Lifesciences given factors such as its earnings growth profile, profit margins, industry, market cap and risk characteristics, rather than relying only on simple peer or industry comparisons. For Edwards Lifesciences, the Fair Ratio is 29.2x, which is well below the current 46.9x P/E. On this measure, the stock appears expensive relative to what the Fair Ratio implies.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Edwards Lifesciences Narrative

Earlier it was mentioned that there is an even better way to understand valuation, and on Simply Wall St that takes the form of Narratives. These let you set out your story for Edwards Lifesciences, link that story to explicit forecasts for revenue, earnings and margins, and then see the fair value those assumptions imply. All of this happens within an easy tool on the Community page that updates when fresh news or earnings arrive and helps you compare that fair value to the current share price so you can judge for yourself whether the stock looks more like a buy or a sell. For example, one Edwards Lifesciences Narrative might line up with the highest analyst fair value of about US$110 based on confidence in product launches and margin expansion, while another might sit nearer the most cautious view of about US$84, reflecting more weight on risks such as tariffs, competition and acquisition impacts.

Do you think there's more to the story for Edwards Lifesciences? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com